RNAi pioneer’s stock faces pivotal year By Investing.com
Arrowhead Pharmaceuticals, Inc. (NASDAQ:), a biopharmaceutical company specializing in RNA interference (RNAi) technology with a market capitalization of $2.73 billion, stands at a critical juncture as it advances its pipeline and seeks to validate its proprietary TRiM platform. According to InvestingPro data, analysts maintain a bullish outlook, with price targets ranging from $23 to $80 per share. The company’s focus on developing medicines to treat intractable diseases by silencing the genes that cause them has positioned it as a key player in the RNAi therapeutics space.
Company Overview
Arrowhead Pharmaceuticals has been developing RNAi-based therapeutics for over 15 years, targeting multiple tissues and disease states. The…
